Ou, S. H., Kwak, E. L., Siwak-Tapp, C., Dy, J., Bergethon, K., Clark, J. W., Camidge, D. R., Solomon, B. J., Maki, R. G., Bang, Y. J., Kim, D. W., Christensen, J., Tan, W., Wilner, K. D., Salgia, R., Iafrate, A. J. (May 2011) Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol, 6 (5). pp. 942-6. ISSN 1556-1380 (Electronic)1556-0864 (Linking)
Abstract
Crizotinib is a dual MET and ALK inhibitor. Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC). Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor.
| Item Type: | Paper |
|---|---|
| Uncontrolled Keywords: | Aged Antibodies, Monoclonal/administration & dosage Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Bevacizumab Carboplatin/administration & dosage Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/pathology Deoxycytidine/administration & dosage/analogs & derivatives Epithelial-Mesenchymal Transition/*drug effects Female *Gene Amplification Humans Protein Kinase Inhibitors/therapeutic use Proto-Oncogene Proteins c-met/*genetics Pyrazoles/*therapeutic use Pyridines/*therapeutic use Receptor Protein-Tyrosine Kinases/*antagonists & inhibitors Receptors, Growth Factor/*genetics Treatment Outcome |
| Subjects: | diseases & disorders > cancer > drugs and therapies diseases & disorders > cancer > cancer types > lung cancer |
| CSHL Authors: | |
| Communities: | CSHL labs > Maki lab |
| Depositing User: | Matt Covey |
| Date: | May 2011 |
| Date Deposited: | 21 Oct 2016 15:17 |
| Last Modified: | 21 Oct 2016 15:17 |
| Related URLs: | |
| URI: | https://repository.cshl.edu/id/eprint/33723 |
Actions (login required)
 |
Administrator's edit/view item |